Maurice Moloney
Revision as of 18:12, 25 January 2010 by Claire Robinson (talk | contribs)
Maurice Moloney is the Director and Chief Executive of Rothamsted Research, assuming the full duties of his post from 15 April 2010. He is the Chief Scientific Officer of SemBioSys Genetics Inc.[1] - a plant biotech company well known for its controversial work on pharma crops (eg producing insulin from safflower seeds). A GM pharma specialist, Moloney has also worked on deriving a blood anti-coagulant from canola.
Previously, Moloney led the Cell Biology group at Calgene, acquired by Monsanto in 1997,[2] At Calgene he developed the world's first transgenic oilseeds, which resulted in RoundUp Ready Canola and other novel crops. Moloney holds more than 300 patents.[3]
Notes
- ↑ New Director for Rothamsted Research, BBSRC press release, 14 January 2010
- ↑ New Director for Rothamsted Research, BBSRC press release, 14 January 2010
- ↑ New Director for Rothamsted Research, BBSRC press release, 14 January 2010
